Cargando…
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593787/ https://www.ncbi.nlm.nih.gov/pubmed/30920142 http://dx.doi.org/10.1002/ajmg.a.61105 |
| _version_ | 1783430124167757824 |
|---|---|
| author | Hughes, Derralynn A. Nicholls, Kathleen Sunder‐Plassmann, Gere Jovanovic, Ana Feldt‐Rasmussen, Ulla Schiffmann, Raphael Giugliani, Robert Jain, Vipul Viereck, Chris Castelli, Jeffrey P. Skuban, Nina Barth, Jay A. Bichet, Daniel G. |
| author_facet | Hughes, Derralynn A. Nicholls, Kathleen Sunder‐Plassmann, Gere Jovanovic, Ana Feldt‐Rasmussen, Ulla Schiffmann, Raphael Giugliani, Robert Jain, Vipul Viereck, Chris Castelli, Jeffrey P. Skuban, Nina Barth, Jay A. Bichet, Daniel G. |
| author_sort | Hughes, Derralynn A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6593787 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | John Wiley & Sons, Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-65937872019-07-10 Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study Hughes, Derralynn A. Nicholls, Kathleen Sunder‐Plassmann, Gere Jovanovic, Ana Feldt‐Rasmussen, Ulla Schiffmann, Raphael Giugliani, Robert Jain, Vipul Viereck, Chris Castelli, Jeffrey P. Skuban, Nina Barth, Jay A. Bichet, Daniel G. Am J Med Genet A Research Letters John Wiley & Sons, Inc. 2019-03-28 2019-06 /pmc/articles/PMC6593787/ /pubmed/30920142 http://dx.doi.org/10.1002/ajmg.a.61105 Text en © 2019 The Authors. American Journal of Medical Genetics Part A published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Research Letters Hughes, Derralynn A. Nicholls, Kathleen Sunder‐Plassmann, Gere Jovanovic, Ana Feldt‐Rasmussen, Ulla Schiffmann, Raphael Giugliani, Robert Jain, Vipul Viereck, Chris Castelli, Jeffrey P. Skuban, Nina Barth, Jay A. Bichet, Daniel G. Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study |
| title | Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study |
| title_full | Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study |
| title_fullStr | Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study |
| title_full_unstemmed | Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study |
| title_short | Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study |
| title_sort | safety of switching to migalastat from enzyme replacement therapy in fabry disease: experience from the phase 3 attract study |
| topic | Research Letters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593787/ https://www.ncbi.nlm.nih.gov/pubmed/30920142 http://dx.doi.org/10.1002/ajmg.a.61105 |
| work_keys_str_mv | AT hughesderralynna safetyofswitchingtomigalastatfromenzymereplacementtherapyinfabrydiseaseexperiencefromthephase3attractstudy AT nichollskathleen safetyofswitchingtomigalastatfromenzymereplacementtherapyinfabrydiseaseexperiencefromthephase3attractstudy AT sunderplassmanngere safetyofswitchingtomigalastatfromenzymereplacementtherapyinfabrydiseaseexperiencefromthephase3attractstudy AT jovanovicana safetyofswitchingtomigalastatfromenzymereplacementtherapyinfabrydiseaseexperiencefromthephase3attractstudy AT feldtrasmussenulla safetyofswitchingtomigalastatfromenzymereplacementtherapyinfabrydiseaseexperiencefromthephase3attractstudy AT schiffmannraphael safetyofswitchingtomigalastatfromenzymereplacementtherapyinfabrydiseaseexperiencefromthephase3attractstudy AT giuglianirobert safetyofswitchingtomigalastatfromenzymereplacementtherapyinfabrydiseaseexperiencefromthephase3attractstudy AT jainvipul safetyofswitchingtomigalastatfromenzymereplacementtherapyinfabrydiseaseexperiencefromthephase3attractstudy AT viereckchris safetyofswitchingtomigalastatfromenzymereplacementtherapyinfabrydiseaseexperiencefromthephase3attractstudy AT castellijeffreyp safetyofswitchingtomigalastatfromenzymereplacementtherapyinfabrydiseaseexperiencefromthephase3attractstudy AT skubannina safetyofswitchingtomigalastatfromenzymereplacementtherapyinfabrydiseaseexperiencefromthephase3attractstudy AT barthjaya safetyofswitchingtomigalastatfromenzymereplacementtherapyinfabrydiseaseexperiencefromthephase3attractstudy AT bichetdanielg safetyofswitchingtomigalastatfromenzymereplacementtherapyinfabrydiseaseexperiencefromthephase3attractstudy |